Supplementary Methods, SupplementaryTables 1-2, and Supplementary Figures 1-7 from MI130004, a Novel Antibody–Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding &lt;i&gt;In Vivo&lt;/i&gt; Activity against HER2-Expressing Tumors